Physician profile
Shane Harris
NPI 1528762879
$506.90
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76.16 | 2024 | |
| Lilly USA, LLC | $61.80 | 2024 | Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $59.60 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $58.72 | 2024 | Spravato, Invega Sustenna |
| Argenx US, INC. | $50.81 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $39.95 | 2024 | Rexulti |
| Mdd US Operations, LLC | $36.12 | 2024 | Gocovri |
| Biogen, INC. | $24.63 | 2024 | Vumerity, Tysabri |
| Ipsen Biopharmaceuticals, INC | $23.12 | 2024 | Dysport |
| Acadia Pharmaceuticals INC | $22.30 | 2024 | Nuplazid |
| Pfizer INC. | $21.41 | 2024 | |
| Tris Pharma INC | $17.25 | 2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $15.03 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.